Larotrectinib is a selective inhibitor of TRK that was tested in three phase I/II clinical trials of 153 cancer patients carrying NTRK fusions (age: 48–67 years) and showed an impressive ORR of 79% and good tolerability [139] (Figure 1). The gene discussed is NTRK1; the disease is cancer.